Daiichi Sankyo's Tumor Drug Meets Primary Endpoint in Late-Stage Study
Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint. Source: BioSpace
Bristol-Myers, Johnson & Johnson Get in on Europeon Biotech Fund's $95M Raise
The money is intended to to fuel European biotech startups. Source: BioSpace
Lundbeck Names Interim Leader, Effective Nov. 1, 2017
Anders Gotzsche will serve as interim CEO while the company looks for a replacement for Kare Schultz who leaves the company Oct. 31 for the CEO position at Teva. Source:…
Why Amazon Could be More Interested in Medical Devices Than Drugs
Amazon, as most everyone knows, has its fingers in a lot of pies. Source: BioSpace
The Complicated Relationship Between Celgene and President Trump
On multiple occasions, President Donald Trump has aimed his ire at pharma companies. Source: BioSpace
Fosun Pharma to Buy France's Tridem for $73M
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa. Source: BioSpace
AstraZeneca Continues to Divest Assets, Takes Stake in Mereo BioPharma With New Deal
Astra signed a licensing deal with Mereo BioPharma to out license the oral inhibitor of neutrophil elastase to the smaller Mereo. Source: BioSpace
Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact
The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace
Merck Drops After Withdrawing European App for Wonder Drug Keytruda
Late on Friday, Merck announced that it had pulled its application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous NSCLC from the EMA.…
Kymera Emerges Out of Stealth Mode With $30M and a Top Team of Drug Hunters
Kymera Therapeutics launched with a $30M Series A financing which was lead by Atlas Venture. Source: BioSpace
- Go to the previous page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- …
- 288
- Go to the next page